Tags

Type your tag names separated by a space and hit enter

The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication.

Abstract

BACKGROUND

This study was performed to evaluate whether the addition of probiotics to proton pump inhibitor (PPI)-based triple therapy increases the likelihood of successful Helicobacter pylori eradication.

MATERIALS AND METHODS

Three hundred and forty-seven H. pylori-infected patients were randomized into a triple-plus-yogurt group (yogurt group, n = 168) or a triple-only group (control group, n = 179). Triple therapy consisted of PPI b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for 7 days. Yogurt group received triple therapy for 1 week and one bottle of Will yogurt per day for at 3 weeks, starting on the first day of triple therapy. Will yogurt (a Korean brand) contains Lactobacillus acidophilus HY2177, Lactobacillus casei HY2743, Bifidobacterium longum HY8001, and Streptococcus thermophilus B-1. (13)C-urea breath test was performed at least 4 weeks after completion of triple therapy. Eradication rates, compliances, and adverse events were compared.

RESULTS

By intention-to treat analysis the H. pylori eradication rates in the yogurt group 79.2% (133 of 168) was similar to that in the control group 72.1% (129 of 179) (p = .124). However, by per-protocol (PP) analysis, the eradication rate in the yogurt group, 87.5% (133 of 152) was higher than that in the control group, 78.7% (129 of 164) (p = .037). Common adverse events were metallic taste (11.8%) and diarrhea (8.6%). The frequency of adverse effects in the yogurt group 41.1% (69/168) were higher than in the control group, 26.3% (47 of 179) (p = .003). However, most adverse events were mild to moderate in intensity, and the severities of adverse effects were similar in both groups (p = .401).

CONCLUSIONS

The addition of Will yogurt to triple therapy did not reduce the side-effects of triple therapy. But it increased the H. pylori eradication rate by PP analysis, encouraging more research in this field.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.

    , , , , , , , , ,

    Source

    Helicobacter 13:4 2008 Aug pg 261-8

    MeSH

    Adolescent
    Adult
    Aged
    Aged, 80 and over
    Amoxicillin
    Breath Tests
    Clarithromycin
    Drug Therapy, Combination
    Female
    Helicobacter Infections
    Helicobacter pylori
    Humans
    Male
    Middle Aged
    Probiotics
    Prospective Studies
    Proton Pump Inhibitors
    Yogurt

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    18665934

    Citation

    Kim, Mi Na, et al. "The Effects of Probiotics On PPI-triple Therapy for Helicobacter Pylori Eradication." Helicobacter, vol. 13, no. 4, 2008, pp. 261-8.
    Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008;13(4):261-8.
    Kim, M. N., Kim, N., Lee, S. H., Park, Y. S., Hwang, J. H., Kim, J. W., ... Song, I. S. (2008). The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter, 13(4), pp. 261-8. doi:10.1111/j.1523-5378.2008.00601.x.
    Kim MN, et al. The Effects of Probiotics On PPI-triple Therapy for Helicobacter Pylori Eradication. Helicobacter. 2008;13(4):261-8. PubMed PMID: 18665934.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. AU - Kim,Mi Na, AU - Kim,Nayoung, AU - Lee,Sang Hyup, AU - Park,Young Soo, AU - Hwang,Jin-Hyeok, AU - Kim,Jin-Wook, AU - Jeong,Sook-Hyang, AU - Lee,Dong Ho, AU - Kim,Joo Sung, AU - Jung,Hyun Chae, AU - Song,In Sung, PY - 2008/7/31/pubmed PY - 2008/9/9/medline PY - 2008/7/31/entrez SP - 261 EP - 8 JF - Helicobacter JO - Helicobacter VL - 13 IS - 4 N2 - BACKGROUND: This study was performed to evaluate whether the addition of probiotics to proton pump inhibitor (PPI)-based triple therapy increases the likelihood of successful Helicobacter pylori eradication. MATERIALS AND METHODS: Three hundred and forty-seven H. pylori-infected patients were randomized into a triple-plus-yogurt group (yogurt group, n = 168) or a triple-only group (control group, n = 179). Triple therapy consisted of PPI b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for 7 days. Yogurt group received triple therapy for 1 week and one bottle of Will yogurt per day for at 3 weeks, starting on the first day of triple therapy. Will yogurt (a Korean brand) contains Lactobacillus acidophilus HY2177, Lactobacillus casei HY2743, Bifidobacterium longum HY8001, and Streptococcus thermophilus B-1. (13)C-urea breath test was performed at least 4 weeks after completion of triple therapy. Eradication rates, compliances, and adverse events were compared. RESULTS: By intention-to treat analysis the H. pylori eradication rates in the yogurt group 79.2% (133 of 168) was similar to that in the control group 72.1% (129 of 179) (p = .124). However, by per-protocol (PP) analysis, the eradication rate in the yogurt group, 87.5% (133 of 152) was higher than that in the control group, 78.7% (129 of 164) (p = .037). Common adverse events were metallic taste (11.8%) and diarrhea (8.6%). The frequency of adverse effects in the yogurt group 41.1% (69/168) were higher than in the control group, 26.3% (47 of 179) (p = .003). However, most adverse events were mild to moderate in intensity, and the severities of adverse effects were similar in both groups (p = .401). CONCLUSIONS: The addition of Will yogurt to triple therapy did not reduce the side-effects of triple therapy. But it increased the H. pylori eradication rate by PP analysis, encouraging more research in this field. SN - 1523-5378 UR - https://www.unboundmedicine.com/medline/citation/18665934/The_effects_of_probiotics_on_PPI_triple_therapy_for_Helicobacter_pylori_eradication_ L2 - https://doi.org/10.1111/j.1523-5378.2008.00601.x DB - PRIME DP - Unbound Medicine ER -